Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.60 |
| ▸ | TDO2 | P48775 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.51 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.51 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.51 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | TEK | Q02763 | 1/20 | 0.50 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | ATR | Q13535 | 1/20 | 0.48 |
| ▸ | UGCG | Q16739 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | AHR | P35869 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5934177 | 0.89 | TRPV1 (0.62) | TRPV1TDO2NPC1RAB9AKCNQ3 | |
| SCHEMBL5934393 | 0.89 | TDO2 (0.58) | TRPV1TDO2KCNQ3KCNQ2KCNE1 | |
| SCHEMBL5934130 | 0.87 | TDO2 (0.56) | TRPV1TDO2NPC1RAB9AKDR | |
| SCHEMBL5934463 | 0.86 | TDO2 (0.58) | TRPV1TDO2KCNQ3KCNQ2KCNE1 | |
| SCHEMBL5934402 | 0.85 | TRPV1 (0.72) | TRPV1NPC1RAB9AKCNQ3KCNQ2 | |
| SCHEMBL5934383 | 0.85 | MEN1 (0.59) | NPC1RAB9AKCNQ3KCNQ2KCNE1 | |
| SCHEMBL5934792 | 0.84 | TRPV1 (0.62) | TRPV1NPC1RAB9AKCNQ3KCNQ2 | |
| SCHEMBL5934290 | 0.84 | MAPT (0.56) | TRPV1NPC1RAB9AKDRCDK9 | |
| SCHEMBL5934304 | 0.83 | NPC1 (0.52) | TRPV1NPC1RAB9AKDRCDK9 | |
| SCHEMBL5934911 | 0.83 | NPC1 (0.52) | TRPV1NPC1RAB9ACDK9ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100245-A1 | Substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100245-A1 | Substituted biphenyl-4-carboxylic acid arylamide analogues | HCAR2, AHR, HCAR3 | TRPV1 53/4885TDO2 1695/4885NPC1 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.